Toxicity of glucocorticosteroids in autoimmune blistering diseases

Year 2019, Volume: 2 Issue: 3, 59 - 67, 29.09.2019

Asli Bilgic Dedee F. Murrell

https://doi.org/10.33204/mucosa.607952

Cited By: 2

Abstract

Glucocorticosteroids (GCs), have been the mainstay treatment for several dermatological diseases such as autoimmune

bullous diseases (AIBDs). However, they come with a great cost of GCs-associated adverse events causing

mortality and morbidity. Recently, a new measure to evaluate toxicity due to GCs’ use has been demonstrated to be

reliable.

This review aimed to summarise toxicity attributed to GCs use and give more insight about this new toxicity index.

Keywords

adverse events, gulcocorticoid, toxicity, dermatology, autoimmune blistering diseases

Otoimmün büllöz hastalıklarda glukokortikosteroid toksisitesi

Abstract

Glukokortikoidler, otoimmün büllöz hastalıklar başta olmak üzere çeşitli dermatolojik hastalıkların temel tedavisi

olmuştur. Bununla birlikte, pek çok morbidite ve mortaliteye neden olan yan etkileri vardır. Son zamanlarda, glukokortikoidlerin kullanımına bağlı toksisiteyi değerlendirmek için yeni bir ölçüm sistemi geliştirilmiş ve güvenilir

olduğu gösterilmiştir.

Bu derleme, glukokortikoidlerin kullanımına bağlı oluşan yan etkileri özetlemeyi ve bu yeni tanıtılan toksisite indeksi

hakkında daha fazla bilgi vermeyi amaçlamaktadır.

Keywords

glukokortikosteroid, yan etkiler, toksisite, dermatoloji, otoimmün büllöz hastalıklar

References

• 1. Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012;32:283-94.
• 2. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015;29:405-14.
• 3. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet 2017;389:2031-40.
• 4. Murrell DF, Peña S, Joly P, et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts.J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30207-X. doi:10.1016/j.jaad.2018.02.021. [Epub ahead of print].
• 5. Bilgic Temel A, Murrell DF. Pharmacological advances in pemphigus. Curr Opin Pharmacol 2019;46:44-9.
• 6. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008;20:131-7.
• 7. Otoimmün Büllöz Hastalıklar Kitabı. Ed. Soner Uzun. Bölüm 5: Otoimmün büllöz hastalıkların tedavisinde kullanılan yöntemler ve öneriler. Uzun S, Eskocak AH. 2a: Sistemik Kortikosteroidler 2017:175-86.
• 8. Burns CM. The history of cortisone discovery and development. Rheum Dis Clin North Am 2016;42:1-14.
• 9. Sulzberger MB, Witten VH, Kopf AW. The topical and systemic use of corticosteroids in the treatment of skin disease. Postgrad Med 1958;24:379-92.
• 10. Nesbitt LT. Glucocorticokortikosteroids. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Spain: Mosby Elsevier; 2008. p. 125.
• 11. Otoimmün Büllöz Hastalıklar Kitabı. Ed. Soner Uzun. Bölüm 5: Otoimmün Büllöz Hastalıkların Tedavisinde Kullanılan Yöntemler ve Öneriler. Uzun S, Bilgiç Temel A. 5-2a: Otoimmün Büllöz Hastalıklarda Yerel Tedavi (5-1a) 2017:161-7.
• 12. http://www.bad.org.uk/shared/get-file.ashx-?id=3427&itemtype=document)
• 13. Mooney E, Rademaker M, Dailey R, et al. Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement.Australas J Dermatol 2015;56:241-51.
• 14. Uzun S. Pemfigusun Güncel Tedavisi ve Yönetimi. Turk J Dermatol 2012;6:91-101.
• 15. Jain SV, Murrell DF. Topical corticosteroids in blistering diseases in: A treatise on topical corticosteroids in dermatology use, misuse and abuse. Ed: Lahiri K. Singapore: Springer Nature Singapore Pte Ltd; 2018 P. 91-100.
• 16. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 2015;172:867-77.
• 17. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000;43:571-94.
• 18. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
• 19. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
• 20. Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis 2017;76:543-6.
• 21. Ehlers L, Wiebe E, Freier D, et al. Prospective use of the glucocorticoid toxicity index (GTI) in a cohort of vasculitis patients. Ann Rheum Dis: first published as 10.1136/annrheumdis-2019-eular.876 on 27 June 2019. http://ard.bmj.com/)
• 22. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15:457-65.
• 23. Jackson SM, Nesbitt LT. Glucocorticosteroids. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. 3rd ed. New York: Elsevier Saunders 2012. p. 2075-88.
• 24. Ram CV, Silverstein RL. Treatment of hypertensive urgencies and emergencies. Curr Hypertens Rep 2009;11:307-14.
• 25. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 2013;17:913-6.
• 26. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515-26.
• 27. Vaishya R, Agarwal AK, Banka PK, Vijay V, Vaish A. Insufficiency fractures at unusual sites: A Case Series. J Orthop Case Rep 2017;7:76-9.
• 28. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine 2012;41:183-90.
• 29. Luo JC, Chang FY, Lin HY, et al. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther 2002;16:1241-8.
• 30. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and metaanalysis. BMJ Open 2014;4:e004587
• 31. Fel A, Aslangul E, Le Jeunne C. Eye and corticosteroid’s use. Presse Med 2012;41:414-21.
• 32. Miller D, Peczon JD, Whitworth CG. Corticosteroids and functions in the anterior segment of the eye. Am J Ophthalmol 1965;59:31-4.
• 33. Munjampalli SK, Davis DE. Medicinal-induced behavior disorders. Neurol Clin 2016;34:133-69.
• 34. Satel SL. Mental status changes in children receiving glucocorticoids: review of the literature. Clin Pediatr 1990;29:382-8.
• 35. Ling MHM, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy: psychiatric aspects. Arch Gen Psychiatry 1981;38:471-7.
• 36. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. J Affect Disord 1983;5:319-32.
• 37. Parikh NS, Schweitzer AD, Young RJ, et al. Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome. J Neurol Sci 2017;380:11-5.
• 38. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 2015;14:914-25.
• 39. Liman TG, Bohner G, Heuschmann PU, Endres M,Siebert E. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol 2012;259:155-64.
• 40. No authors listed. American Academy of Pediatrics Committee on Drugs: The transfer of drugs and other chemicals into human milk. Pediatrics 1994;93:137-50.